Cancer cells have been programmed back to normal by scientists in a breakthrough which could lead to new treatments and even reverse tumour growth. For the first time aggressive breast, lung and bladder cancer cells have been turned back into harmless benign cells by restoring the function which prevents them from multiplying excessively and forming dangerous growths. Scientists at the Mayo Clinic in Florida, US, said it was like applying the brakes to a speeding car. So far it has only been tested on human cells in the lab, but the researchers are hopeful that the technique could one day be used to target tumours so that cancer could be ‘switched off’ without the need for harsh chemotherapy or surgery. “We should be able to re-establish the brakes and restore normal cell function,” said Profesor Panos Anastasiadis, of the Department for Cancer Biology. “Initial experiments in some aggressive types of cancer are indeed very promising. “It represents an unexpected new biology that provides the code, the software for turning off cancer.”
Cells need to divide constantly to replace themselves. But in cancer, the cells do not stop dividing, leading to huge cell reproduction and tumour growth. The scientists discovered that the glue which holds cells together is regulated by biological microprocessors called microRNAs. When everything is working normally the microRNAs instruct the cells to stop dividing when they have replicated sufficiently. They do this by triggering production of a protein called PLEKHA7 which breaks the cell bonds. But in cancer that process does not work. Scientists discovered they could switch on cancer in cells by removing the microRNAs from cells and preventing them from producing the protein. And, crucially they found that they could reverse the process switching the brakes back on and stopping cancer. MicroRNAs are small molecules which can be delivered directly to cells or tumours so an injection to increase levels could switch off disease.
“We have now done this in very aggressive human cell lines from breast and bladder cancer,” added Dr Anastasiadis. “These cells are already missing PLEKHA7. Restoring either PLEKHA7 levels, or the levels of microRNAs in these cells turns them back to a benign state. We are now working on better delivery options.” Henry Scowcroft, Cancer Research UK’s senior science information manager, said: “This important study solves a long-standing biological mystery, but we mustn’t get ahead of ourselves. “There’s a long way to go before we know whether these findings, in cells grown in a laboratory, will help treat people with cancer. But it’s a significant step forward in understanding how certain cells in our body know when to grow, and when to stop. Understanding these key concepts is crucial to help continue the encouraging progress against cancer we’ve seen in recent years.”
The research was published in the journal Nature Cell Biology.
Sarah Knapton, Science Editor of The Telegraph
24 Aug 2015